RIGL — Rigel Pharmaceuticals Inc · P/E 9.1, rev $137.5M

Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.

Latest reported RIGL revenue for 2026-06-30 was $137.5M. Net income was $25.9M. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.

Use this RIGL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RIGL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RIGL SEC filings page. Lician reads the product cache first so this HTML stays unique to Rigel Pharmaceuticals Inc even when a live quote feed is slow.

Rigel Pharmaceuticals Inc latest statements (FY2025)

Latest cached year on this hub. Full RIGL income, balance, and cash tables.

  • Revenue$294.3M
  • Net Income$367.0M
  • Total Assets$513.6M
  • Total Debt$0
  • Free Cash Flow$0

RIGL recent filings